Navigation Links
Long-Term Estrogen Therapy Does Up Breast Cancer Risk: Study
Date:4/2/2012

By Denise Mann
HealthDay Reporter

SUNDAY, April 1 (HealthDay News) -- Several weeks after a study suggested that women who take estrogen-only hormone replacement to treat menopause symptoms may be at lower risk for developing breast cancer, another, much-larger study finds that when used for longer than 10 years, estrogen-only regimens actually raise a woman's long-term risk for breast cancer.

The new study was funded by the National Cancer Institute, part of the U.S. National Institutes of Health, whereas the previous one was partially funded by drug manufacturer Wyeth.

Researchers evaluated follow-up data from the Nurse's Health Study collected from 1980 through 2008. The women in the study were 30 to 55 years old in 1976. Overall, the risk for breast cancer was 88 percent higher among women who had taken estrogen plus progesterone for 10 to 14.9 years, compared to women who did not. This risk more than doubled for women who used estrogen-plus-progesterone therapy for 15 to 19.9 years.

Women who used estrogen-only therapy after menopause had 22 percent increased risk for breast cancer if they used it for 10 to 14.9 years, and 43 percent greater risk if they used it longer than 15 years.

There was no increased risk seen among women who took estrogen for fewer than 10 years. Women did not have an increased risk of dying from breast cancer, the study showed.

Hormone replacement therapy (HRT) fell from grace after the U.S. Women's Health Initiative study was stopped early in 2002 because HRT was shown to increase the risk of strokes and breast and ovarian cancer. Some subtleties have emerged since that time. For example, short-term use of HRT is now deemed fairly safe for some women who have severe menopausal symptoms. Estrogen-only therapy is reserved for women who have had a hysterectomy; women with an intact uterus who use HRT must take the hormone progestin (synthetic progesterone) with estrogen to prevent uterine cancer.

"For combination therapy there is so much data about the dangers that we really tell people that if they must take it to treat symptoms, they should only do so for a year or two at most," said study author Dr. Wendy Chen, an associate physician at Brigham and Women's Hospital and an assistant professor in medicine at the Breast Cancer Treatment Center at the Dana-Farber Cancer Institute in Boston. "For estrogen alone, there is more safety data for someone who wants to take it for five or six years."

Chen is scheduled to present her findings at this week's annual meeting of the American Association for Cancer Research in Chicago.

Her advice is for women to think about why they are taking supplemental hormones. "If it is for hot flashes, they don't last forever," she said. If vaginal dryness is the issue, there are vaginal hormone preparations. "You are not going to have the systemic effects that you will from talking a pill," she said.

Dr. Larry Norton, deputy physician-in-chief for breast cancer programs at Memorial Sloan-Kettering Cancer Center and medical director of the Evelyn H. Lauder Breast Center, in New York City, does not recommend that women take estrogen after menopause.

"The jury is still out on how safe estrogen alone is, but I am not recommending it, and the major reason why is because every drug I know that reduces the risk of breast cancer reduces estrogen," he said. "Saying an estrogen is going to be safe raises an important question mark in my mind," Norton said. "Alternative treatments may help treat the symptoms and risks associated with menopause, so why take the chance?"

Because the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

Learn more about the benefits and risks of HRT through the North American Menopause Society.

SOURCES: Wendy Y. Chen, M.D., MPH., associate physician, Brigham and Women's Hospital and assistant professor in medicine, Breast Cancer Treatment Center, Dana-Farber Cancer Institute, Boston; Larry Norton, M.D., deputy physician-in-chief for breast cancer programs, Memorial Sloan-Kettering Cancer Center, and medical director, Evelyn H. Lauder Breast Center, New York City; abstract, American Association for Cancer Research, annual meeting, March 31-April 4, 2012, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Underestimates Long-Term Costs of Obesity, Experts Say
2. Groundbreaking, long-term study of head injuries among athletes kicks off with NCAA grant
3. HIV/AIDS vaccine shows long-term protection against multiple exposures in non-human primates
4. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
5. Study finds some insulin production in long-term Type 1 diabetes
6. People who retire early due to back problems face long-term financial disadvantage
7. Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients
8. Oxford University Press and Medical Council on Alcohol announce long-term partnership
9. Severe Brain Injury When Young May Have Long-Term Effects
10. Emergency room visits risky for elderly residents from long-term care facilities
11. Nicotine Patches, Gums Wont Help Smokers Quit Long-Term: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Long-Term Estrogen Therapy Does Up Breast Cancer Risk: Study
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: